Research programme: cancer therapeutics - Echelon Biosciences/AMRI Hungary

Drug Profile

Research programme: cancer therapeutics - Echelon Biosciences/AMRI Hungary

Latest Information Update: 27 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AMRI Hungary; Echelon Biosciences
  • Class Small molecules
  • Mechanism of Action Phosphoric monoester hydrolase inhibitors; Phosphotransferase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 May 2007 Albany Molecular Research is now called AMRI
  • 02 Feb 2005 Echelon Biosciences has acquired the rights to all intellectual property associated with its collaboration with ComGenex
  • 11 Jan 2005 Echelon Biosciences has been acquired by AEterna Zentaris
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top